Non-Alcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression.

Ramiro Manzano-NunezMarta Santana-Dominguez Jesus Manuel Rivera EstebanClara SabioteElena SenaJuan BañaresFrank TackeJuan M Pericàs

Published in: Journal of clinical medicine (2023)

The prevalence of NAFLD (43%) among PCOS patients is high despite their average young age, with several metabolic and PCOS-specific factors influencing its occurrence. Screening programs may aid in detecting metabolic-associated fatty liver disease and prevent its consequences. Further work is required to establish the burden of liver-related outcomes once NAFLD has progressed in the PCOS population.

Keyphrases

polycystic ovary syndrome
insulin resistance
systematic review
end stage renal disease
ejection fraction
risk factors
public health
risk assessment
peritoneal dialysis
type diabetes
metabolic syndrome
patient reported
middle aged